H1 2026 sales reached €3,203K, up +44% at constant exchange rates (CER) and +39% as reported1
CellTolerance® sales increased +145% to €0.9 million, driven by strong international expansion
Strong systems pipeline for H2 2026 in the U.S. and new international territories
Confirmed trajectory toward profitability by year-end 2027 supported by sales growth and strengthened balance sheet
Webinar for shareholders and investors – Tuesday, July 21, 2026
5:50 p.m. (CEST) – French Session: Click here to register
Paris and Boston, July 21, 2026 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today reported its sales for the first half of 2026.
First-half 2026 sales reached €3,203K, up 44% at constant exchange rates (+39% as reported), driven by the Company’s two growth engines: the clinical adoption of Cellvizio in pancreatic cysts in the United States and the rapid international expansion of CellTolerance® (EMEA & ROW up 261%). Supported by a strengthened balance sheet — reinforced by the €4 million shareholder loan facility secured in July 2026 with Vester Finance, a long-standing shareholder and financial partner — a growing base of recurring revenue and a solid systems pipeline for the second half, Mauna Kea confirms its trajectory toward profitability by year-end 2027.
Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies, commented: “Since our November 2025 financing, the team has worked relentlessly to strengthen our commercial foundations worldwide while maintaining a very lean organization. In such conditions, I am pleased to report +44% growth at constant exchange rates in the first half of 2026, as well as strong growth in the number of CellTolerance centers in the U.S., our entry into four new markets and the opening of our first centers operating under a direct patient-pay model. We also added four new PPU accounts in the U.S., completed the first deployment of our Cellvizio Link remote data-collection solution and benefited from several important new clinical publications across our core indications. We continue to build solid foundations for durable, profitable growth and have a solid system sales pipeline for the second half of the year. These concrete achievements support our ambition to establish Cellvizio as a reference platform for interventional endoscopy, while opening significant market opportunities for CellTolerance and for additional indications in gastroenterology and beyond.”
1Excluding license revenues
